Four-color flow cytometric analysis of myeloma plasma cells

Am J Clin Pathol. 2006 Dec;126(6):908-15. doi: 10.1309/vwxaraag9dapq31y.

Abstract

We monitored the behavior of residual myeloma plasma cells in patients with multiple myeloma after high-dose therapy and autologous or allogeneic transplantation using 3 methods of a flow cytometric technique using 4-color staining, immunofixation, and polymerase chain reaction approaches. We analyzed 17 cases by a relatively simple flow cytometric technique using CD38/CD45/CD19/CD56. Detectable myeloma plasma cells were found in 5 patients at diagnosis and 9 patients after treatment. Of 14 cases, 9 (64%) had CD19-CD56+ myeloma plasma cells, and 5 (36%) of 14 had CD19-CD56- myeloma plasma cells. When 37 bone marrow samples that had less than 5% myeloma plasma cells were assessed, myeloma plasma cells were detected in all 20 immunofixation-positive cases and 3 of 17 immunofixation-negative cases (P = .002). All 4 polymerase chain reaction-negative samples characterized as immunofixation-negative contained no detectable myeloma plasma cells. Flow cytometry can provide effective information to detect low levels of myeloma plasma cells.

MeSH terms

  • Adult
  • Aged
  • Antigens, CD / analysis
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Biomarkers, Tumor / metabolism
  • Bone Marrow Cells / pathology*
  • Combined Modality Therapy
  • Dexamethasone / therapeutic use
  • Doxorubicin / therapeutic use
  • Etoposide / therapeutic use
  • Female
  • Flow Cytometry / methods*
  • Humans
  • Immunophenotyping / methods*
  • Male
  • Melphalan / therapeutic use
  • Middle Aged
  • Multiple Myeloma / metabolism
  • Multiple Myeloma / pathology*
  • Multiple Myeloma / therapy
  • Staining and Labeling / methods*
  • Stem Cell Transplantation
  • Vincristine / therapeutic use

Substances

  • Antigens, CD
  • Biomarkers, Tumor
  • Vincristine
  • Etoposide
  • Dexamethasone
  • Doxorubicin
  • Melphalan

Supplementary concepts

  • VAD protocol